RBC Capital Maintains Outperform on Karuna Therapeutics, Lowers Price Target to $235
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Karuna Therapeutics (NASDAQ:KRTX) but lowered the price target from $249 to $235.

August 04, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Karuna Therapeutics' price target has been lowered from $249 to $235 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100